NCT05419349

Brief Summary

This study have two aims, the first is to explore the optimal cutoff of TLN for Siewert type II AEG using the Surveillance, Epidemiology, and End Results (SEER) database the second is to provide a more accurate staging for Siewert type II AEG patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,819

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2022

Completed
6 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 7, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 7, 2022

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

June 13, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 15, 2022

Completed
Last Updated

November 4, 2022

Status Verified

June 1, 2022

Enrollment Period

6 days

First QC Date

June 13, 2022

Last Update Submit

November 1, 2022

Conditions

Keywords

esophagogastric junctiontotal examined lymph nodesstaging

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    the time from disease diagnosis to death from any cause

    5-year overall survival

Interventions

esophagogastric junction cancer surgery

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The data were obtained from the SEER public database. In the 18 SEER registries, the 2021 release of the public use dataset from 2004 to 2015 was queried.

You may qualify if:

  • Siewert type for adenocarcinoma of the esophagogastric junction; pathologically confirmed T1-4aN0-3M0 stage after surgery after a pathological examination of the LNs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fujian Medical University Union Hospital

Fuzhou, Fujian, 350001, China

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2022

First Posted

June 15, 2022

Study Start

June 1, 2022

Primary Completion

June 7, 2022

Study Completion

June 7, 2022

Last Updated

November 4, 2022

Record last verified: 2022-06

Data Sharing

IPD Sharing
Will not share

The data were obtained from the SEER public database

Locations